Development and Validation of an HPLC-MS/MS Method for Quantification of Apixaban in Human Plasma

Development and Validation of an HPLC-MS/MS Method for Quantification of Apixaban in Human Plasma

Introduction. Apixaban is an anticoagulant used in a number of thromboembolic diseases with an improved benefit-to-risk ratio, according to multiple clinical studies. Due to the prescription of apixaban as antithrombotic therapy in patients with COVID-19, an increase in its use has been observed. Th...

Full description

Saved in:
Bibliographic Details
Main Authors: U. D. Filonova, P. K. Karnakova, K. K. Karnakova, M. O. Popova, A. A. Popova, O. A. Archakova, T. N. Komarov, I. E. Shohin
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2024-03-01
Series:Разработка и регистрация лекарственных средств
Subjects:
anticoagulants
doac
apixaban
hplc-ms/ms
validation
covid-19
pharmacokinetics
Online Access:https://www.pharmjournal.ru/jour/article/view/1759
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items